SkQ1 and MitoQ share the TPP+, a lipophilic cation that facilitates molecules targeting to mitochondria; the same residue is also present in Mito-Apo, another compound that displayed its neuroprotective effects in AD and PD both in vitro and in vivo providing, respectively, a reduction of neuronal degeneration [162] and an attenuation of motor deficit in PD mouse models when bound to apocynin, a NADPH oxidase inhibitor that counteracts ROS formation [158,163,164]. Here, FMO5 is linked to Parkinson disease.